GE Healthcare, Optellum collaborate for AI-based lung cancer diagnosis GE Healthcare has collaborated with Optellum to progress precision diagnosis and lung cancer treatment with artificial intelligence. The partnership is zeroed in on helping healthcare providers to evaluate the malignancy of a lung nodule a...
Find MorePfizer tightens DMD patient criteria after serious adverse events in phase 3 gene therapy trial Pfizer is tightening up the criteria for Duchenne muscular dystrophy patients to partake in phase 3 clinical trials of its experimental gene therapy after three severe events were cropping up in ongoing studies. Th...
Find MoreA New Dawn for CRISPR, Intellia Edits Cells Inside the Body Intellia Therapeutics, along with its partner Regeneron Pharmaceuticals, recently announced its successful attempt in editing the cells inside the body leveraging the CRISPR technique. The world’s first-ever trial that has their DNA edited through an in...
Find MoreEvery year this month, a lot of campaigns take place to raise awareness about breast cancer, its symptoms, early diagnosis, and treatment options. Much progress has been made to manage breast cancer, assess its risks, prevent it, and treat it by a combination of surgery, radiation, and other treatment. The past dec...
Find MoreBreast cancer is the most common form of cancer in women. Each year, it affects over 2 million women globally and is the most significant cause of death among women. The epidemiological forecasts revealed by the end of 2020, approximately 276,480 women in the United States will be diagnosed with invasive breast can...
Find MoreAstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UK After receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and the University of Oxford have resumed the trials of their experimental coronavirus candidate AZD1222 in the country. A rapid review by the tria...
Find MoreOlema Oncology raises USD 54 Million for breast cancer program Olema Oncology has raised USD 54 million to push its lead program into the clinic and boost its R&D efforts in other areas. The capital will bankroll a phase 1/2 study of the asset, OP-1250, as a single agent. Olema Oncology will a...
Find MoreOrchard licenses the gene therapy technology from GlaxoSmithKline Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to...
Find MoreOver the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...
Find MoreLassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease are...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.